chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysphagia, Rhinorrhoea, Throat tightness
Clinical narrative: Runny nose.; throat closing (thickness); itchy throat; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via unspecified route of administration in the left arm on 10Mar2021 at 16:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no concomitant medication within two weeks of COVID vaccine. The patient was not allergic to any medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Mar2021 at 16:45 (25 minutes after vaccination), the patient experienced runny nose followed by sensation of throat closing thickness, followed by itchy throat; which was possible to breathe through his nose. The patient did not receive any treatment for the reported adverse events. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the event runny nose, itchy throat and throat thickness was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information expected.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rhinorrhoea, Throat irritation, Throat tightness
Clinical narrative: Runny nose.; throat closing (thickness); itchy throat; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via unspecified route of administration in the left arm on 10Mar2021 at 16:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no concomitant medication within two weeks of COVID vaccine. The patient was not allergic to any medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Mar2021 at 16:45 (25 minutes after vaccination), the patient experienced runny nose followed by sensation of throat closing thickness, followed by itchy throat; which was possible to breathe through his nose. The patient did not receive any treatment for the reported adverse events. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the event runny nose, itchy throat and throat thickness was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information expected.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injected limb mobility decreased, Loss of personal independence in daily activities, Pain, Sleep disorder
Clinical narrative: Pain; shoulder and armare still sore; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old female non-pregnant patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6202), via an unspecified route of administration in arm right on 12Mar2021 at 12:15 (at the age of 60-years) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Concomitant medication included unspecified herbal supplement/vitamins taking from over 5 years. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EM9809), via an unspecified route of administration in arm left on 19Feb2021 at 9:15 (at the age of 60-years) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine 4 weeks prior to COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Mar2021 at 13:45, the patient experienced pain less than one day later the vaccination, waited for the pain to resolve but it had not, and it was continuing to get worse, the patient shoulder and arm are still sore, the pain is getting progressively worse and not it hurts to lift the arm when comb the hair or to put dishes in the cabinet but it hurts to lift arm up and it hurts when the patient pick up objects of 8 ounces or more. No therapeutic measures were taken for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event vaccination site pain and pain in arm was not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Vaccination site pain
Clinical narrative: Pain; shoulder and armare still sore; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old female non-pregnant patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6202), via an unspecified route of administration in arm right on 12Mar2021 at 12:15 (at the age of 60-years) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Concomitant medication included unspecified herbal supplement/vitamins taking from over 5 years. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EM9809), via an unspecified route of administration in arm left on 19Feb2021 at 9:15 (at the age of 60-years) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine 4 weeks prior to COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Mar2021 at 13:45, the patient experienced pain less than one day later the vaccination, waited for the pain to resolve but it had not, and it was continuing to get worse, the patient shoulder and arm are still sore, the pain is getting progressively worse and not it hurts to lift the arm when comb the hair or to put dishes in the cabinet but it hurts to lift arm up and it hurts when the patient pick up objects of 8 ounces or more. No therapeutic measures were taken for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event vaccination site pain and pain in arm was not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Chills, Decreased appetite, Diarrhoea, Dizziness
Clinical narrative: Dizziness; Aches; Sweating; Lymph node on the left sideof neck; Fever; Chills; Nausea; Headache; Knee pain; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 18Mar2021 at 16:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure (HBP), penicillin allergy, allergy to nuts and allergy to peaches. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications included atenolol (MANUFACTURER UNKNOWN), triamterene/hctz (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, the patient experienced fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The patient had taken off from work since 22Mar2021.The patient had messaged the doctor on 24Mar2021 and had not received any reply. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The clinical outcomes of the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck were not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Headache, Hyperhidrosis, Impaired work ability, Nausea
Clinical narrative: Dizziness; Aches; Sweating; Lymph node on the left sideof neck; Fever; Chills; Nausea; Headache; Knee pain; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 18Mar2021 at 16:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure (HBP), penicillin allergy, allergy to nuts and allergy to peaches. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications included atenolol (MANUFACTURER UNKNOWN), triamterene/hctz (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, the patient experienced fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The patient had taken off from work since 22Mar2021.The patient had messaged the doctor on 24Mar2021 and had not received any reply. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The clinical outcomes of the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck were not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain, Pain in extremity, Pyrexia, Tinnitus
Clinical narrative: Dizziness; Aches; Sweating; Lymph node on the left sideof neck; Fever; Chills; Nausea; Headache; Knee pain; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 18Mar2021 at 16:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure (HBP), penicillin allergy, allergy to nuts and allergy to peaches. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications included atenolol (MANUFACTURER UNKNOWN), triamterene/hctz (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, the patient experienced fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The patient had taken off from work since 22Mar2021.The patient had messaged the doctor on 24Mar2021 and had not received any reply. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The clinical outcomes of the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck were not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Chills, Dizziness, Headache, Hyperhidrosis
Clinical narrative: Dizziness; Aches; Sweating; Lymph node on the left sideof neck; Fever; Chills; Nausea; Headache; Knee pain; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 18Mar2021 at 16:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure (HBP), penicillin allergy, allergy to nuts and allergy to peaches. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications included atenolol (MANUFACTURER UNKNOWN), triamterene/hctz (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, the patient experienced fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The patient had taken off from work since 22Mar2021.The patient had messaged the doctor on 24Mar2021 and had not received any reply. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The clinical outcomes of the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck were not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Nausea, Pain, Pyrexia
Clinical narrative: Dizziness; Aches; Sweating; Lymph node on the left sideof neck; Fever; Chills; Nausea; Headache; Knee pain; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 18Mar2021 at 16:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure (HBP), penicillin allergy, allergy to nuts and allergy to peaches. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  Concomitant medications included atenolol (MANUFACTURER UNKNOWN), triamterene/hctz (MANUFACTURER UNKNOWN), montelukast sodium (SINGULAIR) and bupropion hydrochloride (WELLBUTRIN), all for unknown indications from unknown dates. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, the patient experienced fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The patient had taken off from work since 22Mar2021.The patient had messaged the doctor on 24Mar2021 and had not received any reply. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck. The clinical outcomes of the events fever, chills, aches, headache, nausea, dizziness, knee pain, sweating and lymph node on the left side of the neck were not recovered at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site pain, Pyrexia, Rash, Rash erythematous
Clinical narrative: Allergic red rash on skin of abdomen developed within 12 h; Rapid heart beat.; Pain in arm where injection was received; itchy; Fever over 101 degrees developed within 12 hours of second dose and continued for nearly 24 hours.; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EP6955) in the left arm via an unspecified route on 22Mar2021 at 13:15 as a single dose (at the age of 72-years-old) for COVID-19 immunisation. Relevant medical history included hyperlipidemia, premature atrial contractions, diverticulosis, seasonal allergies and sinusitis. Patient was allergic to IV contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in the left arm on 22Feb2021 as a single dose for COVID-19 Immunisation. Concomitant medications included atorvastatin calcium (LIPITOR) bifidobacterium bifidum, lactobacillus acidophilus, lactobacillus bulgaricus, lactobacillus casei, lactobacillus rhamnosus, bifidobacterium lactis, lactobacillus plantarum, lactobacillus brevis, lactobacillus salivarius, lactobacillus paracasei, (NATURES BOUNTY PROBIOTIC 10) and camphor, diphenhydramine hydrochloride and zinc oxide (BENADRYL). On 22Mar2021 at 23:00, the patient experienced high fever, 101 degrees, developed within 12 hours of second dose and continued for nearly 24 hours. Extra strength tylenol was taken as a therapeutic measure for fever but did not respond. The patient experienced allergic red rash on skin of abdomen, developed within 12 hours and spread across entire body. The patient experienced pain in arm where injection was received. After 72 hours rash is very itchy but is subsiding. The clinical outcome of the event high fever, red rash on skin of abdomen, rapid heartbeat and vaccination site pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Heart rate increased, Pruritus, Pyrexia, Rash erythematous
Clinical narrative: Allergic red rash on skin of abdomen developed within 12 h; Rapid heart beat.; Pain in arm where injection was received; itchy; Fever over 101 degrees developed within 12 hours of second dose and continued for nearly 24 hours.; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EP6955) in the left arm via an unspecified route on 22Mar2021 at 13:15 as a single dose (at the age of 72-years-old) for COVID-19 immunisation. Relevant medical history included hyperlipidemia, premature atrial contractions, diverticulosis, seasonal allergies and sinusitis. Patient was allergic to IV contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in the left arm on 22Feb2021 as a single dose for COVID-19 Immunisation. Concomitant medications included atorvastatin calcium (LIPITOR) bifidobacterium bifidum, lactobacillus acidophilus, lactobacillus bulgaricus, lactobacillus casei, lactobacillus rhamnosus, bifidobacterium lactis, lactobacillus plantarum, lactobacillus brevis, lactobacillus salivarius, lactobacillus paracasei, (NATURES BOUNTY PROBIOTIC 10) and camphor, diphenhydramine hydrochloride and zinc oxide (BENADRYL). On 22Mar2021 at 23:00, the patient experienced high fever, 101 degrees, developed within 12 hours of second dose and continued for nearly 24 hours. Extra strength tylenol was taken as a therapeutic measure for fever but did not respond. The patient experienced allergic red rash on skin of abdomen, developed within 12 hours and spread across entire body. The patient experienced pain in arm where injection was received. After 72 hours rash is very itchy but is subsiding. The clinical outcome of the event high fever, red rash on skin of abdomen, rapid heartbeat and vaccination site pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain
Clinical narrative: Allergic red rash on skin of abdomen developed within 12 h; Rapid heart beat.; Pain in arm where injection was received; itchy; Fever over 101 degrees developed within 12 hours of second dose and continued for nearly 24 hours.; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EP6955) in the left arm via an unspecified route on 22Mar2021 at 13:15 as a single dose (at the age of 72-years-old) for COVID-19 immunisation. Relevant medical history included hyperlipidemia, premature atrial contractions, diverticulosis, seasonal allergies and sinusitis. Patient was allergic to IV contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in the left arm on 22Feb2021 as a single dose for COVID-19 Immunisation. Concomitant medications included atorvastatin calcium (LIPITOR) bifidobacterium bifidum, lactobacillus acidophilus, lactobacillus bulgaricus, lactobacillus casei, lactobacillus rhamnosus, bifidobacterium lactis, lactobacillus plantarum, lactobacillus brevis, lactobacillus salivarius, lactobacillus paracasei, (NATURES BOUNTY PROBIOTIC 10) and camphor, diphenhydramine hydrochloride and zinc oxide (BENADRYL). On 22Mar2021 at 23:00, the patient experienced high fever, 101 degrees, developed within 12 hours of second dose and continued for nearly 24 hours. Extra strength tylenol was taken as a therapeutic measure for fever but did not respond. The patient experienced allergic red rash on skin of abdomen, developed within 12 hours and spread across entire body. The patient experienced pain in arm where injection was received. After 72 hours rash is very itchy but is subsiding. The clinical outcome of the event high fever, red rash on skin of abdomen, rapid heartbeat and vaccination site pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness
Clinical narrative: Today, 24Mar I am still having dizzy spells and they seem to be getting worse, not better; Having dizzy spells; The handout list dizziness as a sign of an allergic reaction; This is a spontaneous report from a contactable consumer (patient). A 75-year-old non-pregnant female patient received BNT162B2 (COVID-19 VACCINE - MANUFACTURER UNKNOWN, Solution for injection, Batch/Lot Number: EN6199, Expiry date: unknown), dose 1 via an unspecified route of administration, administered in arm right on 11Mar2021 11:45 as dose 1, single for covid-19 immunisation (facility type vaccine: other). Patient was not pregnant at the time of vaccination. Medical history included arthritis and hypertonic bladder, hypersensitivity and allergies to medications, food, or other products. The patient was not diagnosed with COVID-19 since the vaccination and prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Other vaccine in four weeks was reported as no. Other medication in two weeks reported as yes. List of any other medications the patient received within 2 weeks of vaccination: yes. The patient's concomitant medications was not reported. No Covid prior to vaccination and it was unknown if patient was tested post vaccination. The patient experienced having dizzy spells, the handout list dizziness as a sign of an allergic reaction, today, 24Mar i am still having dizzy spells and they seem to be getting worse, not better on 24Mar2021 by doctor or other healthcare professional office/clinic visit. The handout list dizziness as a sign of an allergic reaction. Treatment received for the adverse event: pills for dizziness, which really did not help much. The outcome of events was not recovered.  Follow-up attempts are possible. Further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Condition aggravated, Dizziness, Hypersensitivity
Clinical narrative: Today, 24Mar I am still having dizzy spells and they seem to be getting worse, not better; Having dizzy spells; The handout list dizziness as a sign of an allergic reaction; This is a spontaneous report from a contactable consumer (patient). A 75-year-old non-pregnant female patient received BNT162B2 (COVID-19 VACCINE - MANUFACTURER UNKNOWN, Solution for injection, Batch/Lot Number: EN6199, Expiry date: unknown), dose 1 via an unspecified route of administration, administered in arm right on 11Mar2021 11:45 as dose 1, single for covid-19 immunisation (facility type vaccine: other). Patient was not pregnant at the time of vaccination. Medical history included arthritis and hypertonic bladder, hypersensitivity and allergies to medications, food, or other products. The patient was not diagnosed with COVID-19 since the vaccination and prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Other vaccine in four weeks was reported as no. Other medication in two weeks reported as yes. List of any other medications the patient received within 2 weeks of vaccination: yes. The patient's concomitant medications was not reported. No Covid prior to vaccination and it was unknown if patient was tested post vaccination. The patient experienced having dizzy spells, the handout list dizziness as a sign of an allergic reaction, today, 24Mar i am still having dizzy spells and they seem to be getting worse, not better on 24Mar2021 by doctor or other healthcare professional office/clinic visit. The handout list dizziness as a sign of an allergic reaction. Treatment received for the adverse event: pills for dizziness, which really did not help much. The outcome of events was not recovered.  Follow-up attempts are possible. Further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Body temperature decreased, Bone pain, Fatigue, Migraine
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 22Mar2021 at 10:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included obesity (33.5 BMI with 21% body fat) and allergy to sulfonamide. The patient was allergic to morphine and ondansetron. Concomitant medications included multivitamin supplement (NATUREMADE) received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 01Mar2021 at 11:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 22Mar2021, at 11:15, the patient experienced light-sensitivity migraine, bone and joint pain, altered temperature from (95.9 to 97.1) average temperature was 98.2, reduced mobility, and physical exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events light-sensitivity migraine, bone and joint pain, altered temperature, reduced mobility, and physical exhaustion were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Mobility decreased, Photophobia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 22Mar2021 at 10:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included obesity (33.5 BMI with 21% body fat) and allergy to sulfonamide. The patient was allergic to morphine and ondansetron. Concomitant medications included multivitamin supplement (NATUREMADE) received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 01Mar2021 at 11:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 22Mar2021, at 11:15, the patient experienced light-sensitivity migraine, bone and joint pain, altered temperature from (95.9 to 97.1) average temperature was 98.2, reduced mobility, and physical exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events light-sensitivity migraine, bone and joint pain, altered temperature, reduced mobility, and physical exhaustion were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Body temperature, Body temperature abnormal, Bone pain, Fatigue
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 22Mar2021 at 10:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included obesity (33.5 BMI with 21% body fat) and allergy to sulfonamide. The patient was allergic to morphine and ondansetron. Concomitant medications included multivitamin supplement (NATUREMADE) received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 01Mar2021 at 11:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 22Mar2021, at 11:15, the patient experienced light-sensitivity migraine, bone and joint pain, altered temperature from (95.9 to 97.1) average temperature was 98.2, reduced mobility, and physical exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events light-sensitivity migraine, bone and joint pain, altered temperature, reduced mobility, and physical exhaustion were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Migraine, Mobility decreased
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 22Mar2021 at 10:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history of patient included obesity (33.5 BMI with 21% body fat) and allergy to sulfonamide. The patient was allergic to morphine and ondansetron. Concomitant medications included multivitamin supplement (NATUREMADE) received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 01Mar2021 at 11:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 22Mar2021, at 11:15, the patient experienced light-sensitivity migraine, bone and joint pain, altered temperature from (95.9 to 97.1) average temperature was 98.2, reduced mobility, and physical exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events light-sensitivity migraine, bone and joint pain, altered temperature, reduced mobility, and physical exhaustion were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Rash
Clinical narrative: feel slightly flush/fever; feel slightly flush/fever; Rash across face, neck and chest; This is a spontaneous report received from a contactable consumer (patient) via COVID-19 Adverse Event Self-Reporting Solution (COVAES).   A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 11Mar2021 at 14:30 (at the age of 39-years-old) as a single dose for COVID-19 immunization. Medical history included allergy to red dye in food and medication. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken for an unspecified indication, start and stop date were not reported; paracetamol (TYLENOL), taken for an unspecified indication, start and stop date were not reported.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient experienced feel slightly flush/fever and rash across face, neck and chest on 14Mar2021,at 14:15. Details were as follows: the patient started to feel slightly flush/fever-y and body temperature fluctuated about 0.5-1 degree on 14Mar2021. The feeling lasted about six hours. At the same time, developed a rash across face, neck and chest. The rash was not hives, but small pimple-like bumps. Rash lasted 7 (unit snot reported).  Since the vaccination, the patient has not been tested for COVID-19. The clinical outcome of feel slightly flush/fever was recovered on14Mar2021, at 20:15; the outcome of rash across face, neck and chest was recovered on an unspecified date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Flushing, Pyrexia, Rash
Clinical narrative: feel slightly flush/fever; feel slightly flush/fever; Rash across face, neck and chest; This is a spontaneous report received from a contactable consumer (patient) via COVID-19 Adverse Event Self-Reporting Solution (COVAES).   A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 11Mar2021 at 14:30 (at the age of 39-years-old) as a single dose for COVID-19 immunization. Medical history included allergy to red dye in food and medication. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) taken for an unspecified indication, start and stop date were not reported; paracetamol (TYLENOL), taken for an unspecified indication, start and stop date were not reported.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient experienced feel slightly flush/fever and rash across face, neck and chest on 14Mar2021,at 14:15. Details were as follows: the patient started to feel slightly flush/fever-y and body temperature fluctuated about 0.5-1 degree on 14Mar2021. The feeling lasted about six hours. At the same time, developed a rash across face, neck and chest. The rash was not hives, but small pimple-like bumps. Rash lasted 7 (unit snot reported).  Since the vaccination, the patient has not been tested for COVID-19. The clinical outcome of feel slightly flush/fever was recovered on14Mar2021, at 20:15; the outcome of rash across face, neck and chest was recovered on an unspecified date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral, Lip disorder, Muscle spasms
Clinical narrative: top lip started to spasm and then went numb; tongue numbness; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732), via an unspecified route of administration in the left arm on 25Mar2021 at 03:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and daily women's vitamins (MANUFACTURER UNKNOWN); both from an unknown date and for unspecified indication. The patient previously received cefalexin (KEFLEX) for an unknown indication and from an unknown date and experienced drug allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 04:15, about an hour after vaccination, the patient experienced start of spasm in top lip and then went numb, the tip of tongue went numb as well. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Benadryl and Advil. The clinical outcome of the event tongue numbness was recovered on 27Mar2021 and lip numbness was recovered on 30Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral
Clinical narrative: top lip started to spasm and then went numb; tongue numbness; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732), via an unspecified route of administration in the left arm on 25Mar2021 at 03:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and daily women's vitamins (MANUFACTURER UNKNOWN); both from an unknown date and for unspecified indication. The patient previously received cefalexin (KEFLEX) for an unknown indication and from an unknown date and experienced drug allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 04:15, about an hour after vaccination, the patient experienced start of spasm in top lip and then went numb, the tip of tongue went numb as well. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Benadryl and Advil. The clinical outcome of the event tongue numbness was recovered on 27Mar2021 and lip numbness was recovered on 30Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Impaired work ability, Nausea, Vomiting
Clinical narrative: Indigestion; Vomiting every two hours from 12amuntil 7am; Severe nausea every day at lead for an hour if notlonger regardless of food or drink intake; This is a spontaneous report received from a contactable consumer, the patient. A 21-year-old non pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 18Mar2021 at 09:00 (at the age of 21-years-old), as single dose for COVID-19 immunisation. Medical history included generalized anxiety disorder and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Mar2021 at 00:00, the patient experienced vomiting every two hours until 07:00, severe nausea every day at least for an hour if not longer regardless of food or drink intake and indigestion The adverse events result in a visit to the doctors or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of vomiting, nausea and indigestion and included treatment with ondansetron (MANUFACTURER UNKNOWN) 8mg and loratadine (MANUFACTURER UNKNOWN) 10 mg. The clinical outcome of the vomiting was recovered on 23Mar2021 at 07:00; nausea and indigestion were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspepsia, Nausea, Vomiting
Clinical narrative: Indigestion; Vomiting every two hours from 12amuntil 7am; Severe nausea every day at lead for an hour if notlonger regardless of food or drink intake; This is a spontaneous report received from a contactable consumer, the patient. A 21-year-old non pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 18Mar2021 at 09:00 (at the age of 21-years-old), as single dose for COVID-19 immunisation. Medical history included generalized anxiety disorder and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Mar2021 at 00:00, the patient experienced vomiting every two hours until 07:00, severe nausea every day at least for an hour if not longer regardless of food or drink intake and indigestion The adverse events result in a visit to the doctors or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of vomiting, nausea and indigestion and included treatment with ondansetron (MANUFACTURER UNKNOWN) 8mg and loratadine (MANUFACTURER UNKNOWN) 10 mg. The clinical outcome of the vomiting was recovered on 23Mar2021 at 07:00; nausea and indigestion were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Appetite disorder, Dizziness, Glycosylated haemoglobin, Impaired driving ability, Impaired work ability
Clinical narrative: fever; headache feels like a migraine; light-headed/dizzy; pain continues and left arm; nausea at times; lack of desire to eat at times; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the left arm on 19Mar2021 at 10:15 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications included ascorbic acid (VITAMIN C) and Prednisone (MANUFACTURER UNKNOWN) and Silver (COLLOIDAL SILVER) for unknown indication from unknown date. The patient was allergic to codeine. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 21Mar2021 at 15:00 patient experienced fever, Day 5 still fever most days over 100, headache feels like a migraine, light-headed and dizzy, pain continued and left arm, lack of desire to eat at times. It was reported he missed work for 2 days and unable to drive due to headache and light-headedness. Treatment was taken for the reported events and included ibuprofen for fever and meclizine for dizzy. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events fever, headache, dizzy, pain in arm, nausea and appetite lost was not recovered.   No follow-up attempts possible. No further information expected.